CME in Minutes: Education in Oncology & Hematology

0
Life Sciences #97

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

More
Recent Episodes
  • Aditya Bardia, MD - Sequencing in the Real World With Complex Patient Types, Including Underrepresented Populations
    Jun 2, 2025 – 00:20:47
  • Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Expert-Guided Approaches to Sequencing Strategies With ADCs in HR+, HER2- mBC
    May 29, 2025 – 00:27:14
  • Jesus G. Berdeja, MD - Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap
    May 6, 2025 – 00:17:14
  • Aditya Bardia, MD / Sara Hurvitz, MD - Making a World of Difference for Patients With HER2-Low and -Ultralow Advanced Breast Cancer: Practical Strategies to Integrate Antibody-Drug Conjugates in Special Populations
    Apr 16, 2025 – 00:30:09
  • Aditya Bardia, MD / Sara Hurvitz, MD - Realizing the Potential of Antibody-Drug Conjugates in HER2-Low and -Ultralow Advanced Breast Cancer: Evolving Strategies to Individualize Care
    Apr 10, 2025 – 00:26:25
  • Komal Jhaveri, MD, FACP - Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- Metastatic Breast Cancer
    Apr 10, 2025 – 00:19:18
  • Aditya Bardia, MD / Marilyn M. Bui, MD, PhD - Bringing HER2 Low and Ultralow to Light: How to Define and Detect HER2 Status in Advanced Breast Cancer
    Apr 4, 2025 – 00:21:51
  • Thomas Martin, MD - Focusing on the Frontline: The Impact of Anti-CD38-Based Quadruplet Regimens for Transplant-Ineligible, Newly-Diagnosed Myeloma
    Mar 7, 2025 – 00:15:13
  • Arvind Dasari, MD - Leveling Up Care in the Later-Line Treatment of Metastatic Colorectal Cancer: Bringing Quality of Life to the Forefront
    Jan 31, 2025 – 00:14:21
  • Joshua Richter, MD, FACP - Enhancing Outcomes in Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Harnessing Bispecific Antibodies in Community Care
    Jan 8, 2025 – 00:13:53
  • Jorge Cortes, MD / Elias Jabbour, MD - Care Strategies for Chronic Myeloid Leukemia in Chronic Phase: Customizing Frontline TKI Therapy to Optimize Long-term Patient Outcomes
    Jan 8, 2025 – 00:15:31
  • Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression
    Jan 2, 2025 – 00:13:53
  • Aditya Bardia, MD - Keeping Pace With TROP2-Directed ADCs in HR-Positive, HER2-Negative/Low Advanced Breast Cancer
    Dec 31, 2024 – 00:14:25
  • Sangini S. Sheth, MD, MPH - The Power of Prevention: Patient-Clinician Insights on Increasing HPV Vaccination Uptake to Reduce Cervical Cancer Risk
    Dec 27, 2024 – 00:19:19
  • Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers
    Dec 17, 2024 – 00:14:11
  • Alexander I. Spira, MD, PhD, FACP - Biomarkers at the Forefront: The Crucial Role of Testing Across Solid Tumor Types
    Dec 13, 2024 – 00:15:03
  • David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC
    Dec 12, 2024 – 00:00:31
  • Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Advancing Care in EGFR-Mutated NSCLC: Unveiling New Horizons With ADCs
    Dec 2, 2024 – 00:33:10
  • David Harpole, MD / Neel Chudgar, MD - The Practicalities of Perioperative Immunotherapy for Resectable NSCLC
    Nov 26, 2024 – 00:23:57
  • David Harpole, MD / Nicolas Girard, MD, PhD - Trials and Tribulations: Examining the Data for Perioperative Immunotherapeutic Approaches in Resectable NSCLC
    Nov 20, 2024 – 00:31:02
  • Jia Ruan, MD, PhD - Clinical Case Challenges in Frontline PTCL: Navigating the Landscape of CD30-Positive PTCL Treatment
    Nov 15, 2024 – 00:19:09
  • Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Leveraging Precise Targets to Elevate Outcomes: NSCLC Treatment Strategies for HER2-Directed ADCs
    Nov 15, 2024 – 00:26:31
  • Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice
    Nov 6, 2024 – 00:15:35
  • Jacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs
    Oct 30, 2024 – 00:27:05
  • Richard Kim, MD / Gerald Prager, MD - Evidence-Based Strategies for Optimizing Long-Term Treatment Responses in Later Lines of mCRC Care
    Oct 28, 2024 – 00:17:10
  • Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma
    Oct 28, 2024 – 00:13:42
  • Joyce O'Shaughnessy, MD - Harnessing Immunotherapy for Early Breast Cancer Management: Neoadjuvant Updates in HR-Positive, HER2-Negative Disease
    Sep 19, 2024 – 00:14:37
  • Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens
    Sep 19, 2024 – 00:14:24
  • David M. Miller, MD, PhD / Todd Schlesinger, MD - A Clinician’s Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies
    Sep 13, 2024 – 00:16:17
  • Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization
    Sep 9, 2024 – 00:12:35
  • Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions
    Sep 9, 2024 – 00:12:49
  • Aditya Bardia, MD - From Theory to Practice: Enhancing Antibody-Drug Conjugate Integration in HER2-Low Advanced Breast Cancer
    Aug 9, 2024 – 00:18:36
  • John L. Marshall, MD - Proactive Safety Management Strategies to Extend Survival for Patients With Metastatic CRC
    Aug 9, 2024 – 00:14:38
  • Rami Komrokji, MD - Navigating the First-Line Treatment Landscape of Anemia in Lower-Risk MDS: Translating the Latest Data to Practice
    Aug 5, 2024 – 00:13:13
  • Stephanie E. Combs, MD / Heather Wakelee, MD - A Growing Need for Targeted Approaches in Unresectable Stage III NSCLC: A Clinical Evaluation of Evolving Data in EGFR Mutation–Positive Disease
    Aug 5, 2024 – 00:15:59
  • Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice
    Jul 12, 2024 – 00:12:10
  • Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective
    Jul 12, 2024 – 00:24:37
  • Sagar Lonial, MD, FACP - Accelerating Targeted Degradation in Multiple Myeloma: The Role of CELMoDs in Overcoming IMiD Resistance in Earlier Lines of Therapy
    Jul 4, 2024 – 00:14:27
  • Paul Telfer, MA, DM, BM, BCh, FRCP, FRCPath - Decoding the Future: Bringing Gene Therapy Into Prime Time for Patients With Sickle Cell Disease
    Jul 4, 2024 – 00:13:11
  • Ghassan Abou-Alfa, MD, MBA - Getting On the Right Tract: Patient-Centered Strategies to Diagnose Biliary Tract Cancers
    Jul 4, 2024 – 00:11:47
  • Ticiana Leal, MD - Squaring Off With Squamous NSCLC: The Latest Evidence and Guidance on Chemoimmunotherapy Options
    Jul 4, 2024 – 00:18:53
  • Saad Z. Usmani, MD, MBA, FACP, FASCO - Making the Case for Triple Therapy in R/R Multiple Myeloma: Expert Guidance for Optimizing Anti-CD38 mAb Regimens
    Jun 25, 2024 – 00:14:57
  • Ben Carpenter, MD, PhD - Exploring Novel Therapeutic Frontiers in Transfusion-Dependent Beta Thalassemia: The Path to Transfusion Independence
    Jun 25, 2024 – 00:14:24
  • Josep M. Llovet, MD, PhD - Redefining How to Treat Intermediate-Stage HCC: Exploring TACE Plus Immunotherapy–Based Combination Therapy
    Jun 18, 2024 – 00:13:22
  • Richard Kim, MD - Enhancing Treatment Sequencing to Extend Survival: Tailoring Later-Line Care to the Patient With Metastatic Colorectal Cancer
    May 28, 2024 – 00:15:26
  • Jyoti Mayadev, MD - From Routine Screening to Applying Clinical Advances in Locally Advanced Cervical Cancer: Evolving Care in High-Risk Populations
    Apr 30, 2024 – 00:15:23
  • Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer
    Apr 5, 2024 – 00:13:42
  • Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients
    Apr 5, 2024 – 00:12:52
  • Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician
    Apr 5, 2024 – 00:14:09
  • Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer
    Mar 29, 2024 – 00:20:20
Recent Reviews
Disclaimer: The podcast and artwork on this page are property of the podcast owner, and not endorsed by UP.audio.